Scribd
Upload
32 views8 pages

Sanofi Oncology

Uploaded by

sam.reinereine
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF or read online on Scribd
32 views8 pages

Sanofi Oncology

Uploaded by

sam.reinereine
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF or read online on Scribd
You are on page 1/ 8
= sanofi Q Home > OurScience > R&DFocusAreas > Oncology R&D Breaking New Ground in Oncology We are charging ahead to transform the lives of patients, ease the burden of cancer on society, and restore hope. Illustration of a T cell attacking a tumor cell “We’re determined to develop powerful medicines, that are effective with the best possible safety profile, for people living with cancer. We’re confident we can do so by harnessing the potential of our proprietary drug discovery platforms.” Frank Nestle Chief Scientific Officer Layla Bral, Associate Scientist - LMR Ghent — Nanobody Research Platform Discovery, Belgium Our oncology pipeline We have more than a dozen next-generation molecules in the clinic, each with a distinctive mechanism of action against either hematologic malignancies or solid tumors. Our pipeline > Follow the science Our R&D teams follow the science to find treatments for people living with cancer. Voices from the Lab: Nizar El Murr Our multi-front attack on cancer on Immuno-oncolo: id John Reed and Frank Nestle discuss how we're building an R&D pipeline to address critical gaps in cancer care Watch the video (7 Read the article > Taking Aim at Lung Cancer A promising antibody-drug conjugate enters the clinic Read the article Bolstering the immune system Our immuno- oncology teams are working on ways to boost the immune system to better detect and attack tumors, And our molecular oncology teams are designing powerful precision drugs to either destroy cancer cells or activate immune cells locally. Rethinking oncology drug development Our culture of collaboration empowers our teams to achieve real change for people battling cancer. Technology toolbox We've reshaped our footprint in oncology, expanding our capabilities with state-of-the- art technologies in immuno-oncology, molecular oncology, and genomic medicine. Seemore —> Patient centricity By listening, learning, and keeping patients at the center of everything we do, we can advance the science and make a lasting difference in people's lives. Seemore Collaboration To further our bold vision of generating multiple candidates every year, we collaborate with innovative partners to break new ground in oncology. Seemore > More about oncology eB aN Cancer Under Siege Sanofi’s Commitment to Oncology Read the article — Read the article > Your Health: Oncology Seemore — Selected publications + LaMarche MJ (2022) Think Biologically, Act Chemically. J Medicinal Chem; DOI: 10.1021/acs.jmedchem.2cO1121 + Manandhar M, Chun E, Romesberg FE (2021) Genetic Code Expansion: Inception, Development, Commercialization. J Am Chem Soc 143:4859-4878; DOI: 10.1021/jacs.0c1938, + Mitra-Kaushik S, Mehta-Damani A, Stewart JJ, et al. (2021) The Evolution of Single-Cell Analysis and Utility in Drug Development. APS J 23:98; DOI: 10.1208/s12248-021-00633-6 Page updated August 2023 Continue to Oncology Partnering > MAT-GLB-2002356 v3.0 06/2023 Contact Legal notice Privacy & data protection Cookies Policy Code of Conduct Our publications Sitemap Directory Accessibility: partial compliance Sanofi Today © Sanofi 2004-2023 - All rights reserved

You might also like

pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy